Kantoff PW - Search Results

1

Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.

Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK. Sartor O, et al. Among authors: kantoff pw. Clin Genitourin Cancer. 2009 Oct;7(3):E90-2. doi: 10.3816/CGC.2009.n.030. Clin Genitourin Cancer. 2009. PMID: 19815488

2

New agents in the therapy of hormone-refractory patients with prostate cancer.

Kantoff PW. Kantoff PW. Semin Oncol. 1995 Feb;22(1 Suppl 1):32-4. Semin Oncol. 1995. PMID: 7532323 Review. No abstract available.

3

14-Day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate.

Kantoff PW, Block C, Letvak L, George M. Kantoff PW, et al. Am J Clin Oncol. 1993 Dec;16(6):489-91. doi: 10.1097/00000421-199312000-00005. Am J Clin Oncol. 1993. PMID: 8256762 Clinical Trial.

4

Management of hormone refractory prostate cancer: current standards and future prospects.

Oh WK, Kantoff PW. Oh WK, et al. Among authors: kantoff pw. J Urol. 1998 Oct;160(4):1220-9. J Urol. 1998. PMID: 9751323 Review.

5

Prognostic indicators in hormone refractory prostate cancer.

George DJ, Kantoff PW. George DJ, et al. Among authors: kantoff pw. Urol Clin North Am. 1999 May;26(2):303-10, viii. doi: 10.1016/s0094-0143(05)70070-7. Urol Clin North Am. 1999. PMID: 10361553 Review.

6

A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.

Oh WK, Manola J, Richie JP, Loughlin KR, Kantoff PW. Oh WK, et al. Among authors: kantoff pw. Cancer. 1999 Oct 1;86(7):1329-34. doi: 10.1002/(sici)1097-0142(19991001)86:7<1329::aid-cncr31>3.0.co;2-r. Cancer. 1999. PMID: 10506721 Clinical Trial.

7

Treatment of locally advanced prostate cancer: is chemotherapy the next step?

Oh WK, Kantoff PW. Oh WK, et al. Among authors: kantoff pw. J Clin Oncol. 1999 Nov;17(11):3664-75. doi: 10.1200/JCO.1999.17.11.3664. J Clin Oncol. 1999. PMID: 10550165 Review.

8

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Kantoff PW, et al. J Clin Oncol. 1999 Aug;17(8):2506-13. doi: 10.1200/JCO.1999.17.8.2506. J Clin Oncol. 1999. PMID: 10561316 Clinical Trial.

9

Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.

Oh WK, Kantoff PW. Oh WK, et al. Among authors: kantoff pw. Semin Oncol. 1999 Oct;26(5 Suppl 17):49-54. Semin Oncol. 1999. PMID: 10604270 Review.

10

Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma.

Oh WK, Manola J, Renshaw AA, Brodkin D, Loughlin KR, Richie JP, Shapiro CL, Kantoff PW. Oh WK, et al. Among authors: kantoff pw. Urology. 2000 Jan;55(1):31-5. doi: 10.1016/s0090-4295(99)00408-2. Urology. 2000. PMID: 10654890

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

482 results

Search Page

Filters